動物用生物製剤の市場規模、シェア、成長分析、タイプ別、種別、対象疾患別、供給源別、地域別 - 産業予測、2025～2032年

動物用生物製剤の世界市場規模は、2023年に264億4,000万米ドルと評価され、2024年の275億8,000万米ドルから2032年には386億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.31％で成長する見通しです。

動物用生物製剤市場は、動物の健康重視の高まりと、ペットの健康に対する飼い主の意識の高まりによって顕著な成長を遂げています。ペット飼育の増加と家畜生産の増加がこの分野の拡大をさらに後押ししています。人獣共通感染症の増加は予防措置の必要性を強調し、動物用生物製剤への投資を強化しています。組換えワクチン、DNAワクチンやモノクローナル抗体のような次世代生物製剤、高度なバイオテクノロジープラットフォームなどの技術革新が、この状況を一変させています。さらに、コールドチェーンロジスティクスの改善や遠隔地への広範な働きかけは、ワクチンへのアクセスや有効性を高める上で極めて重要です。全体として、政府の強力な取り組みと共同研究開発の努力は、畜牛、家禽、コンパニオンアニマル、水産養殖を含む様々なセグメントに十分な成長機会をもたらしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• ケーススタディ
• 顧客購買行動分析

動物用生物製剤市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• ワクチン
• 抗生物質
• 駆虫薬
• 成長促進剤

動物用生物製剤市場規模：種別& CAGR（2025-2032）

• 市場概要
• 家畜
• コンパニオンアニマル

動物用生物製剤市場規模：対象疾患別& CAGR（2025-2032）

• 市場概要
• 細菌感染症
• ウイルス感染
• 寄生虫感染症
• 代謝障害

動物用生物製剤市場規模：供給源別& CAGR（2025-2032）

• 市場概要
• 細胞培養
• 不活化された病原体
• 組み換え技術

動物用生物製剤市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Hipra
• Zoetis
• Boehringer Ingelheim
• Tsinghua Tongda
• Bayer Animal Health
• Intervet
• Elanco Animal Health
• Ceva Animal Health
• Vetoquinol
• Beijing SVA Vaccines Serums
• Virbac
• Harbin Veterinary Research Institute
• Shenzhen Kangtai Biological Products
• Chongqing Zhifei Biological Products
• Merck Animal Health

結論と提言

Global Veterinary Biologics Market size was valued at USD 26.44 billion in 2023 and is poised to grow from USD 27.58 billion in 2024 to USD 38.65 billion by 2032, growing at a CAGR of 4.31% in the forecast period (2025-2032).

The veterinary biologics market is experiencing notable growth driven by heightened emphasis on animal health and the rising awareness among pet owners regarding their pets' wellbeing. Increasing pet ownership and livestock production further fuel this sector's expansion. The rise in zoonotic diseases underscores the need for preventive measures, enhancing investment in veterinary biologics. Innovations such as recombinant vaccines, next-generation biologics like DNA vaccines and monoclonal antibodies, and advanced biotechnological platforms are transforming the landscape. Additionally, improved cold chain logistics and extensive outreach to remote areas are crucial for enhancing vaccine access and efficacy. Overall, robust government initiatives and collaborative R&D efforts present ample opportunities for growth across various segments, including cattle, poultry, companion animals, and aquaculture.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Veterinary Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Veterinary Biologics Market Segments Analysis

The veterinary biologics market is segmented into type, species, target disease, source, and region. By type, the market is classified into vaccines, antibiotics, Antiparasitic, and growth promoters. Depending on the species, it is bifurcated into livestock and companion animals. According to target disease, the market is divided into bacterial infections, viral infections, parasitic infections, and metabolic disorders. As per the supported source, it is categorised into cell culture, inactivated pathogens, and recombinant technologies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Veterinary Biologics Market

One of the key market drivers for the Global Veterinary Biologics Market is the increasing prevalence of zoonotic diseases that can be transmitted from animals to humans. As urbanization and human-animal interactions rise, the risk of such diseases escalates, prompting governments and healthcare organizations to prioritize animal health management. This, in turn, drives demand for vaccines and biologics that ensure the health and productivity of livestock and companion animals. Additionally, growing awareness among pet owners regarding animal health and the importance of preventive care further propels the market, as consumers seek effective solutions to protect their animals from infectious diseases.

Restraints in the Global Veterinary Biologics Market

One key market restraint impacting the global veterinary biologics market is the stringent regulatory environment governing the approval and commercialization of veterinary products. The complex and lengthy process for obtaining necessary certifications and licenses can delay market entry for new vaccines and therapeutics, hampering innovation and accessibility. Additionally, varying regulatory standards across countries may complicate international trade and distribution, limiting market potential for manufacturers. These challenges can create barriers for smaller companies and new entrants, fostering an environment where larger, established players dominate, ultimately stifling competition and reducing the overall growth potential of the veterinary biologics sector.

Market Trends of the Global Veterinary Biologics Market

The Global Veterinary Biologics market is experiencing a marked shift towards recombinant DNA and vector-based vaccines, reflecting an industry-wide trend favoring innovative and efficient solutions. This transition from traditional live and inactivated vaccines is driven by the advantages these novel technologies present, such as enhanced safety profiles, strain specificity, and rapid production capabilities, essential for addressing the challenges posed by emerging and mutating diseases. Investments from both established companies and startups in recombinant platforms are increasing, driven by advancements in cell culture and synthetic biology, ultimately aiming to meet the diverse health needs of both companion and large livestock animals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Veterinary Biologics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Vaccines
• Antibiotics
• Antiparasitic
• Growth Promoters

Global Veterinary Biologics Market Size by Species & CAGR (2025-2032)

• Market Overview
• Livestock
• Companion Animals

Global Veterinary Biologics Market Size by Target Disease & CAGR (2025-2032)

• Market Overview
• Bacterial Infections
• Viral Infections
• Parasitic Infections
• Metabolic Disorders

Global Veterinary Biologics Market Size by Source & CAGR (2025-2032)

• Market Overview
• Cell Culture
• Inactivated Pathogens
• Recombinant Technologies

Global Veterinary Biologics Market Size & CAGR (2025-2032)

• North America (Type, Species, Target Disease, Source)
  • US
  • Canada
• Europe (Type, Species, Target Disease, Source)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Species, Target Disease, Source)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Species, Target Disease, Source)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Species, Target Disease, Source)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hipra
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tsinghua Tongda
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing SVA Vaccines Serums
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harbin Veterinary Research Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Kangtai Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations